

A preoperative prediction model for anastomotic leakage after rectal cancer resection based on 13.175 patients

Hoek, V.T.; Buettner, S.; Sparreboom, C.L.; Detering, R.; Menon, A.G.; Kleinrensink, G.J.; ... ; Dutch ColoRectal Audit Grp

Citation

Hoek, V. T., Buettner, S., Sparreboom, C. L., Detering, R., Menon, A. G., Kleinrensink, G. J., ... Wiggers, J. K. (2022). A preoperative prediction model for anastomotic leakage after rectal cancer resection based on 13.175 patients. *European Journal Of Surgical Oncology*, *48*(12), 2495-2501. doi:10.1016/j.ejso.2022.06.016

Version:Not Applicable (or Unknown)License:Licensed under Article 25fa Copyright Act/Law (Amendment Taverne)Downloaded from:https://hdl.handle.net/1887/3564037

Note: To cite this publication please use the final published version (if applicable).

Contents lists available at ScienceDirect

European Journal of Surgical Oncology

journal homepage: www.ejso.com

A preoperative prediction model for anastomotic leakage after rectal cancer resection based on 13.175 patients

V.T. Hoek ^{a, *}, S. Buettner ^a, C.L. Sparreboom ^a, R. Detering ^b, A.G. Menon ^{a, c}, G.J. Kleinrensink ^d, M.W.J.M. Wouters ^{e, f, g}, J.F. Lange ^{a, 1}, J.K. Wiggers ^{h, 1}, On behalf of the Dutch ColoRectal Audit group

^a Department of Surgery, Erasmus University Medical Centre, Rotterdam, the Netherlands

^b Department of Surgery, OLVG, Amsterdam, the Netherlands

^c Department of Surgery, IJsselland Hospital, Capelle aan den IJssel, the Netherlands

^d Department of Neuroscience-Anatomy, Erasmus University Medical Centre, Rotterdam, the Netherlands

^e Department of Biomedical Data Sciences, Leiden University Medical Center, Leiden, the Netherlands

^f Department of Surgical Oncology, Netherlands Cancer Institute-Antoni van Leeuwenhoek, Amsterdam, the Netherlands

^g Scientific Bureau, Dutch Institute for Clinical Auditing, Leiden, the Netherlands

^h Department of Colorectal Surgery, Amsterdam University Medical Centers, University of Amsterdam, Cancer Centre Amsterdam, the Netherlands

A R T I C L E I N F O

Article history: Received 14 February 2022 Received in revised form 10 May 2022 Accepted 13 June 2022 Available online 22 June 2022

Keywords: Rectal cancer surgery Anastomotic leakage Prediction model

ABSTRACT

Introduction: This study aims to develop a robust preoperative prediction model for anastomotic leakage (AL) after surgical resection for rectal cancer, based on established risk factors and with the power of a large prospective nation-wide population-based study cohort.

Materials and methods: A development cohort was formed by using the DCRA (Dutch ColoRectal Audit), a mandatory population-based repository of all patients who undergo colorectal cancer resection in the Netherlands. Patients aged 18 years or older were included who underwent surgical resection for rectal cancer with primary anastomosis (with or without deviating ileostomy) between 2011 and 2019. Anastomotic leakage was defined as clinically relevant leakage requiring reintervention. Multivariable logistic regression was used to build a prediction model and cross-validation was used to validate the model.

Results: A total of 13.175 patients were included for analysis. AL was diagnosed in 1319 patients (10%). A deviating stoma was constructed in 6853 patients (52%). The following variables were identified as significant risk factors and included in the prediction model: gender, age, BMI, ASA classification, neo-adjuvant (chemo)radiotherapy, cT stage, distance of the tumor from anal verge, and deviating ileostomy. The model had a concordance-index of 0.664, which remained 0.658 after cross-validation. In addition, a nomogram was developed.

Conclusion: The present study generated a discriminative prediction model based on preoperatively available variables. The proposed score can be used for patient counselling and risk-stratification before undergoing rectal resection for cancer.

© 2022 Published by Elsevier Ltd.

1. Introduction

Anastomotic leakage (AL) is one of the most complex problems after restorative rectal cancer surgery leading to reoperations, readmission, increased length of hospital stay, a higher risk for postoperative mortality and worse oncologic outcomes [1–6]. Despite many preventive efforts, it remains a major problem with a reported prevalence between 1 and 19% [4,7–9]. Risk factors have extensively been analyzed and include male gender, height of the anastomosis, ASA score, diabetes, obesity, smoking, malnutrition, corticosteroid use, and neo-adjuvant (chemo)radiotherapy [4,8,10–13].







^{*} Corresponding author. Department of Surgery, Erasmus University Medical Centre, Wytemaweg 80 3015 CN Rotterdam, Room Ee-173, the Netherlands. *E-mail address*: v.hoek@erasmusmc.nl (V.T. Hoek).

¹ Both authors contributed equally and should both be considered as last authors.

Patients discussing an operation for rectal cancer with their physician face the difficult surgical decision whether to have a colorectal/coloanal anastomosis or a permanent colostomy. Most patients consider the idea of a colostomy unfavorable and desire an anastomosis. On the other hand, some patients find that restorative rectal surgery is associated with significantly impaired bowel function, and, moreover, wish to avoid the risk of AL. Such patient preferences should play a major role to improve the quality of shared decision-making. Nevertheless, tools that allow patients to adequately understand the benefits, risks, and potential harms of both treatment methods are scarce and mostly insufficient [14]. A recent study developed and validated a nomogram to predict bowel dysfunction following restorative rectal cancer resection [15]. Available prediction models for AL however are based on small number of patients or lack sufficient discriminative power to be used in clinical practice [16–18].

This study aims to develop a preoperative prediction model, designed to be used during shared-decision making, for anastomotic leakage after rectal cancer resection. To ensure validity, the design uses variables that are established risk factors in literature and the power of a large nation-wide cohort.

2. Methods

A development cohort was formed by using the DCRA (Dutch ColoRectal Audit), a mandatory population-based repository of all patients who undergo colorectal cancer resection in the Netherlands. The database includes patient-level data regarding preoperative clinical staging, co-morbidities, operative details, as well as postoperative course and definitive pathological result. For the present study, no ethical approval or informed consent was required under Dutch law. Details regarding collection and methodology of the DCRA dataset have been published previously [19].The TRIPOD (Transparent Reporting of a Multivariable Prediction Model for Individual Prognosis or Diagnosis) statement is followed to report multivariable prediction model development and validation [20].

2.1. Study population

Data was assembled of patients operated between January 1, 2011 and December 31, 2019. Patients aged 18 years or older were included who underwent an elective rectal resection for cancer with primary anastomosis (with or without deviating stoma) and curative intention. The more recent 'sigmoid take-off' definition for rectal carcinoma was not available in this historical dataset. Therefore, the carcinoma had to be located within 150 mm of the anal verge to be defined as rectal carcinoma, similar to clinical trials [21]. Patients who underwent a successful procedure to treat obstruction (by stoma or stent) prior to an elective rectal resection were included. Excluded were patients who underwent acute resection for obstructive cancer because this group entails a different treatment setting (i.e. inevitable higher risk of AL) [22]. Patients who underwent intra-operative radiotherapy or rectal resection as part of cytoreductive surgery and hyperthermic intraoperative chemotherapy for peritoneal metastases (HIPEC) were also excluded.

2.2. Study outcomes

The outcome of the study is anastomotic leakage within 30 days, defined as the need for endoscopic, percutaneous or operative reintervention due to the leakage [23].Within the DCRA database, anastomotic leakage was recorded up to 30 days until the year 2018, afterwards 90 days follow-up was applied [24].

2.3. Predictor variables

Candidate predictor variables were identified by reviewing literature and these variables required to be applicable to the preoperative setting. Variables entered in the model were: age [4], sex [4,8,12,25], BMI [25,26], American Society of Anaesthesiologists (ASA) physical status classification [4,8,25], diabetes [4], lung disease [11], ileo- or colostomy [27], tumor invasion on imaging (clinical T-stage according to TNM) [8,25], tumor height from anal verge as assessed by treating radiologist on pre-treatment sagittal MRI and verified during local multidisciplinary team meeting [8,12,25], neo-adjuvant therapy [8,12,25], and approach (transabdominal (open), transabdominal (scopic), transanal local open, TAMIS, transanal and transabdominal, robot) [4,28].

2.4. Statistical analyses

Summary statistics were provided as whole numbers and percentages for categorical variables, and medians with interquartile range (IQR) for continuous variables. The distribution of categorical variables was tested using the χ^2 test. The distribution of continuous variables was tested using the Mann-Whitney U test. Logistic regression analyses were utilized to determine correlation between the primary outcome and predictor variables. Results from the models were reported as odds ratios (OR) and their corresponding 95% confidence intervals (CI). Continuous predictors were transformed using restricted cubic splines if this improved the model fit. Multiple imputation was used to correct for missing data in the multivariable analysis. Backwards selection based on a p < 0.05 was used to select predictors in the final model from the previously described predictor variables. Linear predictors from the final model were used to construct a point-based score and nomogram for clinical application. Cross-validation using 10 random samples was used to validate the model. Model performance was evaluated using Harrel's C-index, the Brier score, and a calibration plot of the apparent and cross-validated model. The concordance index (C-index) was used to quantify discriminative value, which is comparable to the area under the receiver operating characteristic (ROC) curve [29]. The Brier score is used to measure the difference between observed and predicted survival per stage, 0 signifies total accuracy, whereas a score of 0.250 indicates no prognostic value. The model was validated on patients operated before- and after 2018 to identify whether difference in follow-up time (30 days vs 90 days) affected discriminative value. All analyses were performed using the rms, TableOne, and mice packages for R 4.0.5 (https://cran.r-project.org/). All tests were 2-sided and p < 0.05 defined statistical significance.

3. Results

3.1. Study population

A total of 92.392 patients who underwent colorectal surgery for cancer in the Netherlands were included in the database between 2011 and 2019. After exclusion of patients undergoing colonic surgery (n = 66.055) a total of 26.337 patients remained eligible. Patients were excluded because either emergency surgery was performed (n = 114), intraoperative chemo/radiotherapy was applied (n = 120) or no primary colorectal or coloanal anastomosis was constructed (12.928). Eventually, a total of 13.175 were included for analyses.

3.2. Baseline and perioperative characteristics

Among the patients who were included for analyses, the median age was 66 (IOR 59–72) with a majority of patients being male

(n = 8225, (62%)). 7551 (58%) patients received neoadjuvant radio(chemo)therapy, a laparoscopic approach was performed in 9528 (73%), and a deviating stoma was constructed in 6853 patients (52%). Baseline and perioperative characteristics are provided in Supplementary Table 1.

3.3. Prediction model

3.3.1. Risk factors associated with anastomotic leakage

A total of 1319 (10%) patients were diagnosed with AL. The following parameters were associated with AL in univariable analysis: gender, age, BMI, ASA classification, neoadjuvant radio-therapy, clinical T-stage, approach, procedure, tumor height from anal verge, and deviating ileostomy. Univariable analyses are shown in Table 1.

The definitive multivariable model identified the following variables to independently increase risk for AL: male gender (OR 1.62), ASA III/IV (OR 1.33), BMI (OR 1.11, for each 5 kg/m² increase), short-course radiotherapy 5×5 Gy (OR 1.35), chemoradiotherapy (OR 1.11), and clinical T-stage (T1; reference, T2 (OR 1.12), T3 (OR 1.35), T4 (OR 1.15)). In addition, the following variables reduced the risk for AL: increase in age (non-linear, overall p = 0.0005),

Table 1

Baseline & (post)operative characteristics.

construction of a deviating stoma (OR 0.45), and greater distance between location of the tumor and the anal verge (OR 0.89 for each increase in millimetres). Outcomes of multivariable analyses are shown in Table 2. The model had a C-index of 0.664 for prediction of AL and the Brier score was 0.087. After cross-validation the C-index remained 0.658 and the Brier score remained 0.087. Calibration is plotted in Fig. 1. In patients operated before 2018 (AL recorded up to 30 days) the model had a c-index of 0.653. A c-index of 0.683 was found in those operated after 2018 (AL recorded up to 90 days).

3.4. Development of risk-stratification score

A point weighted risk-stratification score for AL after reconstructive rectal cancer surgery was generated by point estimates obtained from the final multivariable model (Table 2). In addition, a nomogram was composed (Fig. 2). Risk to develop AL was calculated for the three tertiles of patients in the dataset. Prevalence of AL was noted to be 5.0% among patients with a score of 0-138 (low risk), 8.5% among patients scoring 138–165 (intermediate risk), and 16.4% among patients scoring 165 and higher (high risk, p < 0.001, Supplementary Fig. 1).

chanceleakage <th< th=""><th></th><th></th><th>No anastomotic</th><th>Anastomotic</th><th><i>P</i>-</th></th<>			No anastomotic	Anastomotic	<i>P</i> -
Cender Male 11856 (90) 1319 [10] -0.001 Age (years) BMI (lsg/m ⁵ v) 374 [81] -0.001 ASS score ² [/1] 10.291 (90) 1108 [10] 0.005 Mil (lsg/m ⁵ v) 25.7 [23.5, 28.4] 25.9 [23.8, 28.7] 0.012 Comorbidities [/1] 10.291 (90) 1108 [10] 0.005 U/V 1563 (88) 211 [12] -0.011 Comorbidities Myocardinfarction in history 532(88) 71(12) 0.144 Myocardinfarction in bistory 532(88) 71(12) 0.354 Cerebrowasular accident (CVA) 668(90) 71(10) 0.354 Cichemo/Radiotherapy 156 (88) 254 [10] 0.035 Sta Gray 3691 (89) 459 [11] 0.354 Sta Gray 3691 (89) 459 [11] 0.354 Sta Gray 3618 (89) 254 [10] 0.471 Sta Gray 3618 (89) 254 [11] 0.354 Cf Stage T1 567 (92) 59 [8] 0.0015			leakage	leakage	value
GenderMale7200 (88)94 [17]<0001Age (years)Female4572 (92)374 [8]-BMI (kgm ¹¹ ^N)57 [23.5, 28.4]25.9 [23.8, 28.7]0.021BMI (kgm ¹¹ ^N)57 [23.5, 28.4]25.9 [23.8, 28.7]0.021SAS score [*] I/II1563 (88)211 [12]-ComorbiditiesI/I/V1563 (88)211 [12]-ComorbiditiesI/I/V1563 (88)211 [12]-ComorbiditiesI/I/V1563 (88)211 [12]-ComorbiditiesI/I/V1563 (88)214 [11]-ComorbiditiesI/I/V1563 (88)244 [10]0.944Lang disease1300,900146 (10)0.753Daberes1300,900146 (10)0.753Daberes1300,900146 (10)0.753Daberes1300,900146 (10)0.754C(Chemo/Badiotherapy136 (89)524 (10)0.754No556 Gray360 (89)524 (10)0.754Tumor height from anal verge, mm71724 (91)327 [10]127AproachCopen1284 (91)328 [9]-Additional resectionNo624 (89)831 [11]-Additional resectionNo624 (89)831 [11]-Additional resectionNo60 (20)98 [8]-AproachNo62 (83)128 [17]-AproachNo62 (83)61 [2]-Additional resection		-	11856 (90)	1319 [10]	
Benale 4752 (20) 374 [8] 0.000 Age (years) 660 [59.0, 73.0] 650 [58.0, 71.0] <0001	Gender	Male	7280 (88)	945 [12]	<0.001
Age (years) Final and open for a scalar and and para scalar and open for a scalar and and para scalar and and para scalar and and para scalar and scalar and and scalar and scalar and and scalar and and scalar and	Gender	Female	4572 (92)	374 [8]	0.001
Task Stands Stands <thstands< th=""> <thstands< th=""> <thstand< td=""><td>Age (years)</td><td>remaie</td><td>660 [590 730]</td><td>650 [580 710]</td><td><0.001</td></thstand<></thstands<></thstands<>	Age (years)	remaie	660 [590 730]	650 [580 710]	<0.001
AS score I/[I 10.201 (00) 1108 [10] 0.002 (00) Comorbidities II//V 1563 (88) 211 [12]	BMI (kg/m ^{Dev})		25 7 [23 5 28 4]	259 [238 287]	0.012
Instant IIII (IV ISG (R) III (I2) III (I2) Comorbidities Myocardinfarction in histry 15G (R) 2111 (I2) 0.144 Comorbidities Myocardinfarction in histry 532(88) 7(12) 0.144 Heart disease 156(90) 48(10) 0.904 Peripheral vascular disease 156(90) 48(10) 0.707 Lung disease 1022(89) 124(11) 0.354 Cerebrovasulair accident (CVA) 668(90) 71(10) 0.753 Diabetes 1390(90) 146(10) 0.498 Kidney disease 1360(88) 25(12) 0.417 (Chemo)Radiotherapy 3051 (89) 459 [11] - 50 Gray and chemotherapy 3061 (80) 459 [11] - 61 Stage 1 17 324 (91) 328 [9] - 7 50 Gray and chemotherapy 3061 (80) 311 [11] - 61 Stage 1 14 - - - 7 12 Stage 1 138<	ASA score ^c	1/11	10 291 (90)	1108 [10]	0.005
Comorbidities Myocardinfarction in history 532(88) 71(12) 0.144 Heart disease 168(90) 18(10) 0.704 Peripheral vascular disease 459(90) 48(10) 0.704 Comorbidities Gerebrovasular accident (CVA) 668(90) 71(10) 0.753 Diabetes 1390(90) 146(10) 0.754 Chemorbidities 1390(90) 146(10) 0.754 Kidney disease 1390(90) 146(10) 0.754 Chemorbidities 1390(90) 524 (10) 0.764 Kidney disease 1390(90) 459 [11] 50 So Gray and chemotherapy 3074 (91) 327 [10] 52 Ta 50 Gray and chemotherapy 304 (91) 328 [91] 50 Tumor height from anal verge, mm 102 121 12 56 Approach Qene 1928 (91) 196 [9] <0.001		III/IV	1563 (88)	211 [12]	0.000
Heart disease 168(90) 18(10) 0.904 Peripheral vascular disease 459(90) 48(10) 0.707 Lung disease 1022(89) 124(11) 0.354 Cerebrovasulair accident (CVA) 668(90) 71(10) 0.738 Diabetes 1390(90) 146(10) 0.498 (Chemo)Radiotherapy No 4936 (90) 524 (10) 0.364 Sx5 Gray 3691 (80) 459 [11) - 0.056 Sx5 Gray 3074 (91) 327 (10) - 0.057 Ta 50 Gray and chemotherapy 3074 (91) 328 [9] - Ta 50 Gray and chemotherapy 3074 (91) 328 [9] - Ta 50 Gray and chemotherapy 3074 (91) 328 [9] - Ta 54 Gray 3246 (91) 328 [9] - Ta 640 (92) 59 [8] - - Tumor height from anal verge, mm - 1000 [70.0, 120.0] 800 [50.0, 100.0] - Approach Open 129 (91)	Comorbidities	Myocardinfarction in history	532(88)	71(12)	0.144
Peripheral vascular disease450(90)48(10)0.707Lung disease1022(89)124(11)0.354Cerebrovaulari accident (CVA)668(90)11(0)0.733Diabetes1390(90)146(10)0.498Kidney disease1390(90)146(10)0.498(Chemo)Radiotherapy668(80)524 [10]0.3055x5 Gray50 Gray and chemotherapy3691 (89)524 [10]0.3055x5 Gray50 Gray and chemotherapy670 (92)50 [8]0.0057 Stage12710327 [10]12Tumor height from anal verge, mm73624 (91)328 [9]10Approach620 (92)59 [8]1004001Approach660 (92)59 [8]1004001Approach1000 [70.01200]800 [50.01000]4001Approach614 (90)914 [10]1210Approach66 (92)518 [10]1001001Additional resection100 [60)12 [10]100101Additional resectionNo628 (83)128 [10]108Additional resectionNo610 (90)17 [8]1001001Tumor heiler tertartent with decompromosing stent or discopt116 (90)17 [10]1001Surgery ¹ No931(90)110 [10]100110011001Surgery ² NoNo117 [10]1106 [10]1106 [10]11001Surgery ² NoNo110110 [10]1001 </td <td></td> <td>Heart disease</td> <td>168(90)</td> <td>18(10)</td> <td>0.904</td>		Heart disease	168(90)	18(10)	0.904
Image disease Cerebrovasular accident (CVA)102(89)12(1)0.354 (0.000)Diabetes Kichey disease668(90)71(10)0.753 (0.0498)(Chemo)RadiotherapyNo186(80)25(12)0.417 (0.010)Sx5 Gray396 (90)524 (10)0.356 (10)396 (90)524 (10)0.356 (10)cT StageT15x5 Gray367 (32)50 [8]0.005 (10)227 [10]51cT StageT17257 (32)50 [8]0.005 (10)328 [9]0.005Tumor height from anal verge, mmT46624 (89)831 [11]510.001ApproachOpen2828 (91)328 [9]<0.001		Peripheral vascular disease	459(90)	48(10)	0.707
Cerbovasulair accident (CVA)668(90)71(10)0.753Diabetes1390(90)146(10)0.498Kidney disease1396(90)524 [10]0.305Kidney disease4936 (90)524 [10]0.305Sx5 Gray and chemotherapy3691 (89)459 [11].50 Gray and chemotherapy3074 (91)327 [10].cT StageT150 (792)50 [8].Tumor height from anal verge, mmT3640 (92)59 [8].Approach000 pon100.0 [70.0, 120.0]800 [50.0, 100.0]<0.011		Lung disease	1022(89)	124(11)	0.354
Diabetes Diabetes 139(09) 14(10) 0.498 Kidney disease 138(88) 25(12) 0.417 (Chemo)Radiotherapy No 4936 (90) 524 [10] 0.417 5x5 Gray 3691 (89) 459 [11] - 50 Gray and chemotherapy 3074 (91) 327 [10] - cT Stage T1 567 (92) 50 [8] 0.005 Tumor height from anal verge, mm 73 6824 (89) 831 [11] - Approach Open 6824 (90) 831 [11] - Laparoscopic 1900 [70.01,20.0] 80.0 [50.0,100.0] <0.01		Cerebrovasulair accident (CVA)	668(90)	71(10)	0.753
Kidney diseaseIs6(88)25(12)0.417(Chemo)RadiotherapyNo4396 (90)524 (10)0.363No3691 (88)459 (11)12750 Gray and chemotherapy3074 (91)327 (10)127cT StageT1567 (92)50 [8]0.005T23246 (91)328 [9]128128Tumor height from anal verge, mmF4640 (92)59 [8]<0.001		Diabetes	1390(90)	146(10)	0.498
(Chemo)RadiotherapyNo936 (90)524 [10]0.0365x5 Gray5x6 Gray3691 (89)459 [11]5x7 Gray and chemotherapy307 (91)327 [10]cT StageT1567 (92)50 [8]0.055T273324 (91)328 [9]Tumor height from anal verge, mmF4640 (92)59 [8]Approach0pen1928 (91)196 [9]<0.01		Kidney disease	186(88)	25(12)	0.417
5x5 Gray 589 (18) 459 [11] 50 Gray and chemotherapy 3074 (91) 327 [10] 50 Gray and chemotherapy 3074 (91) 327 [10] 50 Gray and chemotherapy 3074 (91) 327 [10] 71 50 Gray and chemotherapy 50 Gray and chemotherapy 50 Gray and chemotherapy 72 3246 (91) 328 [9] 328 [9] 72 3246 (91) 328 [9] 50 Gray and chemotherapy 640 (92) 59 [11] 50 Gray and chemotherapy 640 (92) 59 [12] 7 Tumor height from anal verge, mm 1000 [70.0, 120.0] 800 [50.0, 100.0] <0.001	(Chemo)Radiotherapy	No	4936 (90)	524 [10]	0.036
So Gray and chemotherapy307 (19)327 [10]cT StageT1567 (92)50 [8]0.05T1326 (91)328 [9]328 [9]328 [9]10T2324 (80)331 [11]10 </td <td></td> <td>5x5 Gray</td> <td>3691 (89)</td> <td>459 [11]</td> <td></td>		5x5 Gray	3691 (89)	459 [11]	
cT Stage T1 567 (92) 50 [8] 0.005 T2 T2 3246 (91) 328 [9] 328 [9] Tumor height from anal verge, mm 6824 (89) 831 [11] 59 [8] <0.001		50 Gray and chemotherapy	3074 (91)	327 [10]	
F2 Tamper being from anal verge, minF2 Ta Ta F4S246 (91)S28 (9)S31 (11)Tumor height from anal verge, minF4640 (92)5 (8)<0.010	cT Stage	T1	567 (92)	50 [8]	0.005
T3 Tumor height from anal verge, mmT3 T46824 (89)831 [11]59Approach640 (92)59 [8]<001		T2	3246 (91)	328 [9]	
T4 640 (92) 59 [8] Tumor height from anal verge, mm 100.0 [70.0, 120.0] 80.0 [50.0, 100.0] <0.01		T3	6824 (89)	831 [11]	
Tumor height from anal verge, mm100.0 [70.0, 120.0]80.0 [50.0, 100.0]<0.01ApproachOpen1928 (91)196 [9]<0.01		T4	640 (92)	59 [8]	
Approach Open 1928 (91) 196 [9] <0.001 Laparoscopic 8614 (90) 914 [10] - Transanal and open 4 (67) 2 [3] - Transanal Minimally Invasive Surgery ^b 96 (96) 4 [4] - Transanal and laparoscopic 628 (83) 128 [17] - Additional resection No 11,495 (90) 1285 [10] 0.667 Advanced 190 (92) 17 [8] - - Type of resection Elective 161 (90) 17 [0] - Tumor related complications prior to No 35(92) 7(8) - Surgical procedure Low anterior resection 9931(90) 1109(10) 0.843 Surgical procedure Low anterior resection 9931(90) 1109(10) - Surgical procedure Low anterior resection 10420(91) 1178(10) -<001	Tumor height from anal verge, mm		100.0 [70.0, 120.0]	80.0 [50.0, 100.0]	< 0.001
Laparoscopic 8614 (90) 914 [10] Transanal and open 4 (67) 2 [33] Transanal Minimally Invasive Surgery ^b 96 (96) 4 [4] Transanal and Iaparoscopic 628 (83) 128 [17] Robot-assisted 502 (88) 66 [12] Additional resection No 11,495 (90) 1285 [10] 0.667 Advanced 190 (92) 17 [8] 17 [10] 17 [10] Type of resection Elective 11,765 (90) 1312 (10) 0.483 Elective after treatment with decompromosing stent or deviating \$69(2) 1312 (10) 0.483 surgery ^a Yes 1916 (90) 1109 (10) 0.484 surgery ^a Ko 1916 (90) 100 (10) 0.484 surgery ^a Ko 1916 (90) 100 (10) 0.484 surgery ^a Ko 1916 (90) 1109 (10) 0.484 surgery ^a Ko 1916 (90) 100 (10) 0.484 surgery ^a Ko 1916 (90) 100 (10) 0.484	Approach	Open	1928 (91)	196 [9]	< 0.001
Image: Franksand and open 4 (67) 2 [3] Transand Minimally Invasive Surgery ^b 96 (96) 4 [4] Transanal and laparoscopic 628 (83) 128 [17] Robot-assisted 502 (88) 66 [12] Additional resection No 11,495 (90) 1285 [10] 0.667 Advanced 190 (92) 17 [8] Type of resection Elective after treatment with decompromosing stent or deviating 85(92) 768) Tumor related complications prior to No Surgery ^a Yes Deviating Stoma Periating Stoma No Privating Stoma No Type of resection Subor of colectomy Yes <		Laparoscopic	8614 (90)	914 [10]	
Image:		Transanal and open	4 (67)	2 [33]	
Transanal and laparoscopic 628 (83) 128 [17] Robot-assisted 502 (88) 66 [12] Additional resection No 11,495 (90) 1285 [10] 0.667 Advanced 190 (92) 17 [8] 17 Type of resection Elective 11,765 (90) 1312 (10) 0.483 Elective after treatment with decompromosing stent or deviating store or deviating stor deviating store or deviating store or deviating store		Transanal Minimally Invasive Surgery ^b	96 (96)	4 [4]	
Robot-assisted 502 (88) 66 [12] Additional resection No 11,495 (90) 1285 [10] 0.667 Advanced 190 (92) 17 [8] 17 [0] 17 [0] 17 [0] 17 [0] 18 [00) 17 [10] 18 [00) 0.483 Type of resection Elective after treatment with decompromosing stent or deviating stent or deviating stent or deviating steng steng regery ^d 85(92) 7(8) 1109(10) 0.484 surgery ^d No 9931(90) 1109(10) 0.844 surgery ^d Yes 1916(90) 210(10) .844 Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001		Transanal and laparoscopic	628 (83)	128 [17]	
Additional resection No 11,495 (90) 1285 [10] 0.667 Advanced 190 (92) 17 [8] 17 18 Type of resection Limited 161 (90) 17 [10] 0.483 Elective after treatment with decompromosing stent or deviating 85(92) 7(8) 1109(10) 0.483 surgery ^{al} No 9931(90) 1109(10) 0.844 surgery ^{al} Yes 1916(90) 210(10) 0.844 Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001		Robot-assisted	502 (88)	66 [12]	
Advanced 190 (92) 17 [8] Limited 161 (90) 17 [10] Type of resection 161 (90) 17 [10] Elective 11,765 (90) 1312(10) 0.483 Elective after treatment with decompromosing stent or deviating 85(92) 7(8) Tumor related complications prior to No 9931(90) 1109(10) 0.844 surgery ^{al} Yes 1916(90) 210(10) . Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001	Additional resection	No	11,495 (90)	1285 [10]	0.667
Limited 161 (90) 17 [10] Type of resection Elective 11,765 (90) 1312(10) 0.483 Elective after treatment with decompromosing stent or deviating 85(92) 7(8) 7(8) Tumor related complications prior to No 9931(90) 1109(10) 0.844 surgery ^{al} Yes 1916(90) 210(10) . Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001		Advanced	190 (92)	17 [8]	
Type of resection Elective Elective after treatment with decompromosing stent or deviating stomy 11,765 (90) 1312(10) 0.483 Tumor related complications prior to surgery ^{al} No 9931(90) 1109(10) 0.844 Surgical procedure Low anterior resection 9931(90) 1109(10) 0.844 Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001		Limited	161 (90)	17 [10]	
Elective after treatment with decompromosing stent or deviating stent or devi	Type of resection	Elective	11,765 (90)	1312(10)	0.483
Tumor related complications prior to surgery ^a No 9931(90) 1109(10) 0.844 Surgical procedure Yes 1916(90) 210(10) 0 Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001		Elective after treatment with decompromosing stent or deviating stomy	85(92)	7(8)	
Surgery ^{al} Yes 1916(90) 210(10) Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001	Tumor related complications prior to	No	9931(90)	1109(10)	0 844
Surgical procedure Low anterior resection 10,420(91) 1178(10) <0.001 Partial Mesorectal Excision 1177(91) 119(9)	surgery ^a	Yes	1916(90)	210(10)	0.011
Partial Mesorectal Excision 1177(91) 119(9) Subtotal colectomy 28(88) 4(12) Deviating Stoma No 5550 (88) 769 [12] <0.001	Surgical procedure	Low anterior resection	10.420(91)	1178(10)	< 0.001
Subotal colectomy 28(88) 4(12) Deviating Stoma No 5550 (88) 769 [12] <0.001		Partial Mesorectal Excision	1177(91)	119(9)	
Deviating Stoma No 5550 (88) 769 [12] <0.001 Yes 6303 (92) 550 [8]		Subtotal colectomy	28(88)	4(12)	
Yes 6303 (92) 550 [8]	Deviating Stoma	No	5550 (88)	769 [12]	< 0.001
		Yes	6303 (92)	550 [8]	

^a (i.e. anemia, obstruction, abcess.

^b Transanal Minimally Invasive Surgery was followed by Total Mesorectal Excision.

^c American Society of Anesthesiology score.



Fig. 1. Calibration model performance

Apparent: AL predicted versus actually observed. The model overvalues slightly when AL is predicted to be >20%, which means that the model predicts slightly higher AL rates then actually observed. Bias-corrected: AL predicted versus actually observed after cross-validation.

Table	2
-------	---

Multivariable Cox proportional regression analysis.

	Points	Odds ratio	95% CI	p-value
Male gender	26	1.62	(1.79-9.17)	<0.0001
Age	a	a	a	0.005
BMI, 5 kg/m2	6	1.11	(1.03 - 1.19)	0.0046
Stoma				
None	43	Ref	_	-
Deviating Stoma	0	0.45	(0.39-0.51)	< 0.0001
ASA III/IV	15	1.33	(1.13-1.57)	0.0007
Radiotherapy				0.0002
None	0	Ref	_	_
5x5 Gy	16	1.35	(1.17-1.56)	< 0.0001
50 Gray and chemotherapy	5	1.11	(0.93-1.32)	0.2504
cT Stage				0.0273
T1	0	Ref	_	_
T2	6	1.12	(0.81-1.53)	0.5013
T3	16	1.35	(0.99 - 1.84)	0.0669
T4	7	1.15	(0.75 - 1.70)	0.5687
Tumor height from anal verge, mm	-6	0.89	(0.87-0.90)	<0.0001

^a Variable due to restricted cubic splines; 0.08 x Age - 0.001 x Age ^ 3 + 0.003 x Age ^ 3-0.001 x Age ^ 3; C-index of 0.66365 and Brier score of 0.0872.

4. Discussion

Anastomotic leakage remains one of the most dreadful complications within colorectal surgery. Over the last decades AL rates have been reduced, although the average AL rate of rectum surgery is still two times higher than colon surgery [4,7–9]. Given the potential morbidity and even mortality after a leakage, appropriate risk-stratification before surgery is critical to help better predict AL. Using a cohort of 13.175 patients who underwent an elective rectum resection for cancer, the present study developed an accurate pre-operative risk-stratification tool to identify patients at high risk for AL. With the inclusion of a deviating ileostomy in the model, the risk-stratification tool transparently shows the risk reduction which could be gained by construction of such a stoma. Moreover, the model can be used for patient counselling prior to their operation. Identification of high-risk patients may assist during shared decision making, when patients and their physician plan to create an anastomosis (with or without deviating ileostomy) or maybe choose for a permanent colostomy instead.

Previous studies have identified multiple risk factors for AL after rectum surgery but failed to produce an established prediction model. Attempts have been made but most prediction models lacked accuracy or applicability to a preoperative clinical setting. For example, Watanabe et al. introduced a prediction model for AL after rectum surgery and mainly focused on preoperative baseline characteristics without considering imaging related data such as



tumor size and distance to the anal verge [16]. Eventually a c-index of 0.625 for AL was found, which is lower than the c-index in the present study. Zheng et al. included preoperative and perioperative variables, including duration of operation, anastomotic bleeding and surgical approach [28]. Obviously, the addition of these extra variables increased discriminative power of the model, and the authors reported a c-index of 0.722. However, perioperative variables preclude use of the model during shared decision making before surgery. The Rectal Anastomotic Leak score used variables that were comparable to those used in the present study [18]. Nevertheless, the reported c-index was 0.585, which can be considered a relatively poor model. The candidate risk factors in the present study were selected by reviewing literature. Noteworthy, a higher age was associated with a risk reduction in the model. Although counter intuitive, this finding is supported by previous studies [30–35]. An experimental study found that aging tissues develop more chronic inflammation without overt infection, which may contribute to more subclinical-instead of severe morbidity in elderly patients [30,36]. Subclinical AL was not reported in the current database. Other explanations include selection of the fittest and survivor bias [30]. Despite the 'protective' effect of age, mortality rates of elderly patients following AL increases drastically [30,37,38]. Clinical T stage three was associated with a higher risk for AL compared to patients with a clinical T stage four carcinoma. Bias might have been introduced by preoperative selection of patients with favourable expected outcome, while high-risk patients with a T4 staged carcinoma were excluded from surgical curative treatment. The finding that short-course radiotherapy $(5 \times 5Gy)$ is associated with a larger increase in risk for AL compared to chemoradiation has been described previously [39,40].

Within the current prediction model, deviating ileostomy was included. Although this is an operative variable, the decision to construct a stoma is often based on preoperatively available characteristics. Absence of a deviating ileostomy was pointed out as a strong predictor for AL requiring reintervention. A deviating stoma could effectively prevent patients from developing severe symptomatic AL which has been demonstrated previously [41–43]. Importantly, it should be considered that AL on itself is not reduced but severe morbidity requiring reinterventions is minimized [44]. Despite the potential benefits, it should be taken into account that a stoma introduces the risk for additional complications during reversal and could have significant impact on quality of life [1,45]. Therefore, the current risk-stratification tool might help to identify those who will potentially benefit from a deviating stoma and preserve patients who do not need a stoma due to low risk.

The present study had several limitations that need to be addressed. Only leakages that required reintervention were considered in the definition of AL, and subclinical leakages, which may be prevalent especially among patients with a deviating ileostomy, were not registered. Furthermore, the definition slightly changed during the study period. AL was recorded up to 30 days postoperatively in patients operated until 2017 and up to 90 days since 2018, after it was shown leakages are also diagnosed beyond 30 days [24]. Nonetheless, validation showed comparable model performance in both study periods, with even slightly better discriminative power for patients with a 90-day follow-up. Although this study used a comprehensive list of patient characteristics and imaging variables, a few potential risk factors, such as corticosteroid use and smoking, were not available in the DCRA database and therefore not considered in the model. It is recommended to subject the model to external validation on another population-based repository.

Despite these limitations, the strength of the present study was that results were based on a nationwide cohort representing a population which could not be affected by selection bias based on required informed consent. In addition, the large sample size induces statistical power to detect differences between risk factors and generate an accurate prediction model. Furthermore, heterogeneity was minimized by considering rectum surgery for cancer only. Finally, all parameters included in the risk-stratification tool are commonly known, clearly defined, and therefore easily accessible in a clinical setting. With a c-index <0.7 the prediction model lacks discriminative value. Based on the strengths described, it should be considered that the current model has approached the maximum discriminative value which could be obtained from the currently known, preoperatively available, parameters associated with AL. However, there is much to gain in terms of discriminative value which means that there is still a lot to discover with regards to the pathophysiology of AL. Therefore, the colorectal community should strive for identification of additional (out of the box) factors that could compromise anastomotic healing such as expertise, microbiomes, macro/micro vascular calcification, or modifiable risk factors (i.e. preoperative haemoglobin, hyperglycemia, antibiotic prohylaxis and analgesia) [46–48].

The present study generated a discriminative prediction model based on preoperatively available variables. The proposed score can be used for patient counselling and risk-stratification before undergoing rectal resection for cancer.

CRediT authorship contribution statement

V.T. Hoek: Conceptualization, Methodology, Investigation, Data Validation, Writing – original draft. S. Buettner: Data curation, Methodology, Investigation, Writing – original draft. C.L. Sparreboom: Conceptualization, Data curation, Methodology, Investigation, Writing – original draft. R. Detering: Data curation, Methodology, Investigation, Writing – review & editing. A.G. Menon: Conceptualization, Methodology, Writing – review & editing, Supervision. G.J. Kleinrensink: Conceptualization, Methodology, Writing – review & editing, Supervision. M.W.J.M. Wouters: Conceptualization, Methodology, Writing – review & editing, Supervision. J.F. Lange: Conceptualization, Methodology, Writing – review & editing, Supervision, Methodology, Writing – review & editing, Supervision, Methodology, Original draft, Supervision.

Declaration of competing interest

On behalf of the REPAIR research group of the Erasmus University Medical Center (Rotterdam, the Netherlands), I am very pleased to send you this manuscript entitled "A preoperative prediction model for anastomotic leakage after rectal cancer resection based on 13.175 patients" for peer review to *European Journal of Surgical Oncology* on behalf of the following authors V.T. Hoek, M.D, S. Buettner, M.D. Phd.D, C.L. Sparreboom M.D. Ph.D., R. Detering, M.D. Ph.D., A.G. Menon, M.D. Ph.D., G.J. Kleinrensink Ph.D., M.W.J.M. Wouters, M.D. Ph.D., J.F. Lange, M.D. Ph.D., J.K. Wiggers M.D. Ph.D. All authors have read and complied with the author guidelines and did declare there is no conflict of interest.

Appendix A. Supplementary data

Supplementary data to this article can be found online at https://doi.org/10.1016/j.ejso.2022.06.016.

References

- den Dulk M, Smit M, Peeters KC, Kranenbarg EM, Rutten HJ, Wiggers T, et al. A multivariate analysis of limiting factors for stoma reversal in patients with rectal cancer entered into the total mesorectal excision (TME) trial: a retrospective study. Lancet Oncol 2007;8(4):297–303.
- [2] Kawada K, Sakai Y. Preoperative, intraoperative and postoperative risk factors for anastomotic leakage after laparoscopic low anterior resection with double stapling technique anastomosis. World J Gastroenterol 2016;22(25):5718–27.
- [3] Teloken PE, Spilsbury K, Platell C, Committee BO. Analysis of mortality in colorectal surgery in the Bi-national colorectal cancer audit. ANZ J Surg 2016;86(6):454–8.
- [4] Parthasarathy M, Greensmith M, Bowers D, Groot-Wassink T. Risk factors for anastomotic leakage after colorectal resection: a retrospective analysis of 17 518 patients. Colorectal Dis 2017;19(3):288–98.

- [5] Snijders HS, Wouters MW, van Leersum NJ, Kolfschoten NE, Henneman D, de Vries AC, et al. Meta-analysis of the risk for anastomotic leakage, the postoperative mortality caused by leakage in relation to the overall postoperative mortality. Eur J Surg Oncol 2012;38(11):1013–9.
- [6] Kang J, Choi G-S, Oh JH, Kim NK, Park JS, Kim MJ, et al. Multicenter analysis of long-term oncologic impact of anastomotic leakage after laparoscopic total mesorectal excision: the Korean laparoscopic colorectal surgery study group. Medicine 2015;94(29):e1202.
- [7] Paun BC, Cassie S, MacLean AR, Dixon E, Buie WD. Postoperative complications following surgery for rectal cancer. Ann Surg 2010;251(5):807–18.
- [8] McDermott FD, Heeney A, Kelly ME, Steele RJ, Carlson GL, Winter DC. Systematic review of preoperative, intraoperative and postoperative risk factors for colorectal anastomotic leaks. Br J Surg 2015;102(5):462–79.
- [9] Frouws MA, Snijders HS, Malm SH, Liefers GJ, Van de Velde CJH, Neijenhuis PA, et al. Clinical relevance of a grading system for anastomotic leakage after low anterior resection: analysis from a national cohort database. Dis Colon Rectum 2017;60(7):706–13.
- [10] Slieker JC, Komen N, Mannaerts GH, et al. Long-term and perioperative corticosteroids in anastomotic leakage: a prospective study of 259 left-sided colorectal anastomoses. Archives of; 2012.
- [11] Kang CY, Halabi WJ, Chaudhry OO, Nguyen V, Pigazzi A, Carmichael JC, et al. Risk factors for anastomotic leakage after anterior resection for rectal cancer. JAMA Surg 2013;148(1):65–71.
- [12] Pommergaard HC, Gessler B, Burcharth J, et al. Preoperative risk factors for anastomotic leakage after resection for colorectal cancer: a systematic review and meta-analysis. Colorectal 2014.
- [13] Park JS, Huh JW, Park YA, Cho YB, Yun SH, Kim HC, et al. Risk factors of anastomotic leakage and long-term survival after colorectal surgery. Medicine (Baltim) 2016;95(8):e2890.
- [14] Ivatury SJ, Durand MA, Elwyn G. Shared decision-making for rectal cancer treatment: a path forward. Dis Colon Rectum 2019;62(12):1412–3.
- [15] Guo G, Chen X, He W, Wang H, Wang Y, Hu P, et al. Establishment of inflammation biomarkers-based nomograms to predict prognosis of advanced colorectal cancer patients based on real world data. PLoS One 2018;13(12): e0208547.
- [16] Watanabe T, Miyata H, Konno H, Kawai K, Ishihara S, Sunami E, et al. Prediction model for complications after low anterior resection based on data from 33,411 Japanese patients included in the National Clinical Database. Surgery 2017;161(6):1597–608.
- [17] Klose J, Tarantino I, von Fournier A, Stowitzki MJ, Kulu Y, Bruckner T, et al. A nomogram to predict anastomotic leakage in open rectal surgery-hope or hype? J Gastrointest Surg 2018;22(9):1619–30.
- [18] Arezzo A, Migliore M, Chiaro P, Arolfo S, Filippini C, Di Cuonzo D, et al. The REAL (REctal Anastomotic Leak) score for prediction of anastomotic leak after rectal cancer surgery. Tech Coloproctol 2019;23(7):649–63.
- [19] Van Leersum NJ, Snijders HS, Henneman D, Kolfschoten NE, Gooiker GA, ten Berge MG, et al. The Dutch surgical colorectal audit. Eur J Surg Oncol 2013;39(10):1063-70.
- [20] Collins GS, Reitsma JB, Altman DG, Moons KG. Transparent reporting of a multivariable prediction model for individual prognosis or Diagnosis (TRIPOD): the TRIPOD statement. Ann Intern Med 2015;162(1):55–63.
- [21] Breugom AJ, van Gijn W, Muller EW, Berglund A, van den Broek CBM, Fokstuen T, et al. Adjuvant chemotherapy for rectal cancer patients treated with preoperative (chemo)radiotherapy and total mesorectal excision: a Dutch Colorectal Cancer Group (DCCG) randomized phase III trial[†]. Ann Oncol 2015;26(4):696–701.
- [22] The European Society of Coloproctology collaborating g. Safety of primary anastomosis following emergency left sided colorectal resection: an international, multi-centre prospective audit. Colorectal Dis 2018;20(S6):47–57.
- [23] Rahbari NN, Weitz J, Hohenberger W, Heald RJ, Moran B, Ulrich A, et al. Definition and grading of anastomotic leakage following anterior resection of the rectum: a proposal by the International Study Group of Rectal Cancer. Surgery 2010;147(3):339–51.
- [24] Borstlap WAA, Westerduin E, Aukema TS, Bemelman WA, Tanis PJ. Dutch snapshot research G. Anastomotic leakage and chronic presacral sinus formation after low anterior resection: results from a large cross-sectional study. Ann Surg 2017;266(5):870–7.
- [25] Qu H, Liu Y, Bi DS. Clinical risk factors for anastomotic leakage after laparoscopic anterior resection for rectal cancer: a systematic review and metaanalysis. Surg Endosc 2015;29(12):3608–17.
- [26] Nugent TS, Kelly ME, Donlon NE, Fahy MR, Larkin JO, McCormick PH, et al. Obesity and anastomotic leak rates in colorectal cancer: a meta-analysis. Int J Colorectal Dis 2021;36(9):1819–29.
- [27] Peeters K, Tollenaar R, Marijnen CAM, et al. Risk factors for anastomotic failure after total mesorectal excision of rectal cancer. British Journal of 2005.
- [28] Zheng H, Wu Z, Wu Y, Mo S, Dai W, Liu F, et al. Laparoscopic surgery may decrease the risk of clinical anastomotic leakage and a nomogram to predict anastomotic leakage after anterior resection for rectal cancer. Int J Colorectal Dis 2019;34(2):319–28.
- [29] Harrell Jr FE, Lee KL, Mark DB. Multivariable prognostic models: issues in developing models, evaluating assumptions and adequacy, and measuring and reducing errors. Stat Med 1996;15(4):361–87.
- [30] Zaimi I, Sparreboom CL, Lingsma HF, Doornebosch PG, Menon AG, Kleinrensink G-J, et al. The effect of age on anastomotic leakage in colorectal cancer surgery: a population-based study. J Surg Oncol 2018;118(1):113–20.

- [31] Krarup PM, Jorgensen LN, Andreasen AH, Harling H, Danish Colorectal Cancer G. A nationwide study on anastomotic leakage after colonic cancer surgery. Colorectal Dis 2012;14(10):e661–7.
- [32] Jannasch O, Klinge T, Otto R, Chiapponi C, Udelnow A, Lippert H, et al. Risk factors, short and long term outcome of anastomotic leaks in rectal cancer. Oncotarget 2015;6(34):36884–93.
- [33] Midura EF, Hanseman D, Davis BR, Atkinson SJ, Abbott DE, Shah SA, et al. Risk factors and consequences of anastomotic leak after colectomy: a national analysis. Dis Colon Rectum 2015;58(3):333–8.
- [34] Nikolian VC, Kamdar NS, Regenbogen SE, Morris AM, Byrn JC, Suwanabol PA, et al. Anastomotic leak after colorectal resection: a population-based study of risk factors and hospital variation. Surgery 2017;161(6):1619–27.
- [35] Parthasarathy M, Greensmith M, Bowers D, Groot-Wassink T. Risk factors for anastomotic leakage after colorectal resection: a retrospective analysis of 17 518 patients. Colorectal Dis 2017;19(3):288–98.
- [36] Franceschi C, Capri M, Monti D, Giunta S, Olivieri F, Sevini F, et al. Inflammaging and anti-inflammaging: a systemic perspective on aging and longevity emerged from studies in humans. Mech Ageing Dev 2007;128(1): 92–105.
- [37] Bakker IS, Grossmann I, Henneman D, Havenga K, Wiggers T. Risk factors for anastomotic leakage and leak-related mortality after colonic cancer surgery in a nationwide audit. Br J Surg 2014;101(4):424–32. ; discussion 32.
- [38] Tevis SE, Carchman EH, Foley EF, Heise CP, Harms BA, Kennedy GD. Does anastomotic leak contribute to high failure-to-rescue rates? Ann Surg 2016;263(6):1148–51.
- [39] Matthiessen P, Hallböök O, Rutegård J, Sjödahl R. Population-based study of risk factors for postoperative death after anterior resection of the rectum. Br J Surg 2006;93(4):498–503.
- [40] Duldulao MP, Lee W, Le M, Wiatrek R, Nelson RA, Chen Z, et al. Surgical complications and pathologic complete response after neoadjuvant

European Journal of Surgical Oncology 48 (2022) 2495-2501

chemoradiation in locally advanced rectal cancer. Am Surg 2011;77(10): 1281-5.

- [41] Matthiessen P, Hallböök O, Rutegård J, Simert G, Sjödahl R. Defunctioning stoma reduces symptomatic anastomotic leakage after low anterior resection of the rectum for cancer: a randomized multicenter trial. Ann Surg 2007;246(2):207–14.
- [42] Gu WL, Wu SW. Meta-analysis of defunctioning stoma in low anterior resection with total mesorectal excision for rectal cancer: evidence based on thirteen studies. World | Surg Oncol 2015;13:9.
- [43] Mrak K, Uranitsch S, Pedross F, Heuberger A, Klingler A, Jagoditsch M, et al. Diverting ileostomy versus no diversion after low anterior resection for rectal cancer: a prospective, randomized, multicenter trial. Surgery 2016;159(4): 1129–39.
- [44] Shiomi A, Ito M, Maeda K, Kinugasa Y, Ota M, Yamaue H, et al. Effects of a diverting stoma on symptomatic anastomotic leakage after low anterior resection for rectal cancer: a propensity score matching analysis of 1,014 consecutive patients. J Am Coll Surg 2015;220(2):186–94.
 [45] Tsunoda A, Tsunoda Y, Narita K, Watanabe M, Nakao K, Kusano M. Quality of
- [45] Tsunoda A, Tsunoda Y, Narita K, Watanabe M, Nakao K, Kusano M. Quality of life after low anterior resection and temporary loop ileostomy. Dis Colon Rectum 2008;51(2).
- [46] van Praagh JB, de Goffau MC, Bakker IS, van Goor H, Harmsen HJM, Olinga P, et al. Mucus microbiome of anastomotic tissue during surgery has predictive value for colorectal anastomotic leakage. Ann Surg 2019;269(5).
 [47] Huisman DE, Reudink M, van Rooijen SJ, Bootsma BT, van de Brug T, Stens J,
- [47] Huisman DE, Reudink M, van Rooijen SJ, Bootsma BT, van de Brug T, Stens J, et al. LekCheck: a prospective study to identify perioperative modifiable risk factors for anastomotic leakage in colorectal surgery. Ann Surg 2020.
- [48] Hoek VT, Edomskis PP, Menon AG, Dwarkasing RS, Kleinrensink GJ, Jeekel J, et al. Calcification of the aorta-iliac trajectory as a risk factor for anastomotic leakage in colorectal surgery: individual patient data meta-analysis and systematic review. Surg Technol Int 2021;39.